Of­fer 288 out of 416 from 04/06/18, 08:06


Tech­ni­sche Uni­ver­si­tät Dres­den - Cen­ter for Mole­cu­lar and Cel­lu­lar Bio­en­gi­nee­ring (CMCB), Cen­ter for Rege­ne­ra­tive The­ra­pies Dres­den (CRTD), Junior Rese­arch Group “iPS Cells and Neu­ro­de­ge­ne­ra­tive Disease"

The TU Dres­den is one of ele­ven Ger­man uni­ver­si­ties that were iden­ti­fied as an “excel­lence uni­ver­sity”. TUD has about 36.500 stu­dents and almost 5319 employees, 507 pro­fes­sors among them, and, thus, is the lar­gest uni­ver­sity in Sax­ony, today.

Having been com­mit­ted to sci­en­ces and the engi­nee­ring before the reuni­fi­ca­tion of Ger­many, TU Dres­den now is a multi-disci­pline uni­ver­sity, also offe­ring huma­nities and social sci­en­ces as well as medi­cine.

Rese­arch Asso­ciate / PhD Posi­tion

(Sub­ject to per­so­nal qua­li­fi­ca­tion, employees are remu­n­e­ra­ted accord­ing to salary group E 13 TV-L)
The posi­tion starts ide­ally Novem­ber 1st 2018, ent­ails 65% of the full­time weekly hours and is initi­ally limi­ted until Janu­ary 31st 2020 with an optio­nal exten­sion. The period of employ­ment is gover­ned by the Fixed Term Rese­arch Con­tracts Act (Wis­sen­schafts­zeit­ver­trags­ge­setz - Wiss­ZeitVG). The posi­tion offers the chance to obtain a fur­ther aca­de­mic qua­li­fi­ca­tion (e.g. PhD).
Dr. Ster­ne­ckert’s group uses pati­ent spe­ci­fic indu­ced plu­ri­po­tent stem (iPS) cells to gene­rate models of neu­ro­de­ge­ne­ra­tive disea­ses, inclu­ding Par­kin­son’s disease (PD) and amyo­tro­phic late­ral scle­ro­sis. Using a com­bi­na­tion of gene edit­ing, pro­teo­mics, and small mole­cu­les, we aim at under­stan­ding the mecha­nism(s) of patho­ge­ne­sis and iden­ti­fy­ing novel tre­at­ments.

Work­ing field:

The aim of this pro­ject is to use iPS cell-deri­ved neu­rons to model Par­kin­son’s disease, par­ti­cu­larly the role of phase sepa­ra­tion and axo­nal traf­fi­cking. These models will be used for a high-through­put scree­ning cam­paign to iden­tify novel the­ra­peutic com­pounds in close coope­ra­tion with the Lead Dis­co­very Cen­ter GmbH and the teams of Simon Alberti and Ant­hony Hyman (Max Planck Insti­tute of Mole­cu­lar Cell Bio­logy and Gene­tics), as well as Tho­mas Gas­ser (Her­tie Insti­tute for Cli­ni­cal Brain Rese­arch).


We seek highly moti­va­ted, ambi­tious, and talen­ted sci­en­tists to join our enthu­si­a­s­tic and col­la­bo­ra­tive team in an out­stan­ding sci­en­ti­fic envi­ron­ment. We expect the fol­lo­wing: an out­stan­ding uni­ver­sity degree (Mas­ter or equi­va­lent) in Bio­logy, Bio­me­di­cine or simi­lar. Signi­fi­cant expe­ri­ence with cell cul­ture is requi­red. Expe­ri­ence with iPS cell cul­ture, and/or CRISPR/Cas9 media­ted gene edit­ing are pre­fer­red. Expe­ri­ence with mole­cu­lar/bio­che­mi­cal methods, inclu­ding wes­tern blot­ting, plas­mid con­struc­tion/pre­pa­ra­tion, and immu­n­ofluo­re­scence are hel­pful. In addi­tion, app­li­cants are requi­red to have the ability to work in an inter­na­tio­nal team; inter- and mul­ti­di­sci­pli­nary thin­king; high moti­va­tion; an inte­gra­tive and coope­ra­tive per­so­na­lity with excel­lent com­mu­ni­ca­tion and social skills; flu­ency in Eng­lish – writ­ten and oral.

What we of­fer:

App­li­ca­ti­ons from women are par­ti­cu­larly wel­come. The same app­lies to people with disa­bi­li­ties.
Rese­arch Envi­ron­ment
The Cen­ter for Rege­ne­ra­tive The­ra­pies Dres­den (CRTD) is an inter­di­sci­pli­nary insti­tute at the CMCB with a rese­arch cen­ter and Clus­ter of Excel­lence, com­pri­sing 18 core rese­arch groups. Com­ple­men­ting these core groups is the CRTD Mem­bers net­work, an inter­di­sci­pli­nary orga­niza­t­ion of around 80 prin­ci­pal inves­ti­ga­tors loca­ted at other rese­arch insti­tu­tes in Dres­den inclu­ding the Carl Gus­tav Carus Faculty of Medi­cine and the Max Planck Insti­tute of Mole­cu­lar Cell Bio­logy and Gene­tics (MPI-CBG).
Our mis­sion is to under­stand the bio­logy of stem cells and phy­sio­lo­gi­cal and patho­lo­gi­cal tis­sue and organ repair in order to deve­lop new tre­at­ments for neu­ro­de­ge­ne­ra­tive disea­ses, such as Alz­hei­mer's disease and Par­kin­son's disease, hae­ma­to­lo­gi­cal disea­ses, such as leu­ke­mia, meta­bo­lic disea­ses, such as dia­be­tes, and bone disea­ses. Our sci­en­tists are encou­ra­ged to think out­s­ide the box and to explore untap­ped areas of know­ledge in the rege­ne­ra­tive poten­tial of the human body, and to apply this know­ledge to prevent or reverse disease pro­ces­ses.
To achieve our aims, we stron­gly sup­port inter­di­sci­pli­nary rese­arch wit­hin the CRTD net­work where we have exper­tise in ever­y­thing from the bio­logy of cells and tis­sues to bio­ma­te­ri­als to nano­en­gi­nee­ring. CRTD has become a major dri­ving force on cam­pus and is ready to meet the chal­len­ges of moving new inter­ven­tio­nal stra­te­gies from bench to bedside.

How to ap­ply:

Please sub­mit your app­li­ca­tion by June 29th 2018 (stam­ped arri­val date app­lies) pre­fe­r­a­bly via the TU Dres­den Secu­re­Mail Por­tal ( by sen­ding it as a sin­gle pdf docu­ment to or via cen­tral mail ser­vice to the fol­lo­wing address: TU Dres­den, CRTD, Frau Daniela Moh­rich, Fet­scher­str. 105, 01307 Dres­den, Ger­many. Please sub­mit copies only as your app­li­ca­tion will not be retur­ned to you. Expen­ses incur­red in atten­ding inter­views can­not be reim­bur­sed.